Genzyme revenue grows 30%

Genzyme reported yesterday that its third-quarter revenue grew 30% compared with the same period a year ago, rising to $569.2 million from $437.0m.

This increase was driven by growth across the company’s diversified range of innovative healthcare products and services.

GAAP net income for the third quarter was $97.8m, or $0.42 per diluted share, compared with a net loss of $95.7m, or $0.43 per diluted share, for the same quarter last year.